Claims

1. A pharmaceutical composition for use in the treatment of Polypoidal Choroidal Vasculopathy (PCV) comprising an anti-VEGF agent, wherein the treatment comprises
    a. an initial anti-VEGF-therapy
    b. a subsequent evaluation of the treatment response
    c. a subsequent single or repeated combination treatment comprising anti-VEGF-therapy in case the patient does not responds to the initial VEGF therapy.
2. A pharmaceutical composition for use in the treatment of PCV according to claim 1 wherein the combination treatment comprises PDT with Visudyne® and wherein
    a. the pharmaceutical composition for anti-VEGF-therapy is administered to the patient and
    b. subsequently a PDT treatment with Visudyne® is performed at the same day as the anti-VEGF-therapy or 1-7 or 2-3 days after anti-VEGF-therapy.
3. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein the initial anti-VEGF-therapy comprises a single injection or two, three, four, five, six or more injections of the pharmaceutical composition for anti-VEGF therapy each 4, 8, 12 or more weeks apart.
4. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein at least 3 doses of the anti-VEGF-therapy are administered every 4 weeks.
5. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein the evaluation of the treatment response is performed 4, 8, 12 or more weeks after the preceding anti-VEGF-therapy.
6. A pharmaceutical composition for use in the treatment of PCV according to claim 1 wherein the secondary combination therapy is performed one, two, three, four, five, six or more times each 4, 8, 12 or more weeks apart.

7. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD-type or non-AMD type and then in case of AMD-type an AMD treatment is selected.
8. A pharmaceutical composition for use in the treatment of PCV according to claim 7, wherein the selected AMD treatment is a monotherapy.
9. A pharmaceutical composition for use in the treatment of PCV according to claim 8, wherein the monotherapy comprises an anti-VEGF agent.
10. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is treated with a combination therapy including thermal laser therapy, which includes sub-threshold treatments.
11. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is treated with a combination therapy including single or repeated applications of photodynamic therapy with Visudyne® (V®-PDT).
12. A pharmaceutical composition for use in the treatment of PCV according to claim 1 - 11, wherein the anti-VEGF agent is selected from the group consisting of aflibercept, ranibizumab, bevacizumap, or pegaptanip.
13. A pharmaceutical composition for use in the treatment of PCV according to claim 1 - 12, wherein the anti-VEGF agent is aflibercept.

Claims

1. Use of aflibercept in the manufacture of a medicament for the treatment of Polypoidal Choroidal Vasculopathy (PCV), wherein the treatment comprises
    a. an initial therapy comprising aflibercept
    b. a subsequent evaluation of the treatment response
    c. a subsequent single or repeated combination treatment comprising aflibercept in case the patient does not respond to the initial therapy.
2. Use of aflibercept in the manufacture of a medicament for the treatment of PCV according to claim 1 wherein the combination treatment comprises Photodynamic Therapy (PDT) with verteporfin and wherein
    a. aflibercept is to be administered to the patient and
    b. subsequently a PDT treatment with verteporfin is to be performed at the same day as the aflibercept administration or 1-7 or 2-3 days after the aflibercept administration.
3. Use of aflibercept in the manufacture of a medicament for the treatment of PCV according to claim 1, wherein the initial therapy comprises a single injection or two, three, four, five, six or more injections of aflibercept each 4, 8, 12 or more weeks apart.
4. Use of aflibercept in the manufacture of a medicament for the treatment of PCV according to claim 1, wherein the evaluation of the treatment response is to be performed 4, 8, 12 or more weeks after the preceding therapy comprising aflibercept.
5. Use of aflibercept in the manufacture of a medicament for the treatment of PCV according to claim 1 wherein the subsequent combination therapy is to be performed one, two, three, four, five, six or more times each 4, 8, 12 or more weeks apart.
6. Use of aflibercept in the manufacture of a medicament for the treatment of PCV wherein it is to be first established if the PCV is of AMD-type or non-AMD type and then in case of AMD-type the patient is to be treated with a monotherapy comprising aflibercept.

7. Use of aflibercept in the manufacture of a medicament for the treatment of PCV wherein it is to be first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is to be treated with a combination therapy including single or repeated applications of PDT with verteporfin.